Human resources with expertise and experience

We cure patients by developing innovative and clinically applicable diagnostics and therapeutic solutions

EdisBiotech is a company founded to save patients' lives and contribute to their health.
We have extensive experience in basic, translational, and clinical research on gastrointestinal diseases, which show a very high prevalence in South Korea.
Based on this, we are currently developing anti-cancer drugs (neutralizing antibodies, bi-specific antibodies, and antibody drug conjugates) and companion diagnostic tools to target biomarkers discovered from clinical samples.

We aim to take a step closer to diagnosing and overcoming diseases by utilizing technology, know-how, and domestic and international networks established through years of our path.

In addition, we endeavor to create a corporate culture that realizes the dreams of our employees and fulfills social responsibilities. We will grow into a global company that contributes to the healthy life of mankind.

CEOSeung Jae MyungSeung Jae Myung

CEO Seung Jae Myung


  • Graduate : Seoul National University, College of Medicine
  • CEO, Edisbiotech
  • Professor of Medicine, Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine
  • Director, Digestive Diseases Research Center, University of Ulsan College of Medicine
  • KAIST adjunct professor (2017~2022)
  • Director, Biomedical Research Center, Asan Institute for Life Sciences (2015 ~ 2020)
  • President, Korean Association for the Study of Intestinal Diseases (KASID) (2022~2023)
  • Seoul National Univerisy Bio CEO course 17th group (2017)

Research Experiences

  • Director, Center for Bio-imaging of New Drug Development (2014~2019)
  • Global networking and collaborator research (Dana Farber, Wisconsin, etc)
  • Oncogenic mechanism and biomarker study in GI cancers
  • Translational research on GI diseases (Therapeutics, diagnostics, molecular imaging)
  • A number of government-funded grants (A grade)
  • Over 450 SCI paper publications and over 100 clinical studies
  • Over 40 patents
    [domestic 22, PCT 5, international 12, utility model 2, trade mark 1]